Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News MaxCyte Inc MXCT

Technology Scientific & Technical Instruments
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MXCT)

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

GlobeNewswire November 13, 2024

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

GlobeNewswire November 6, 2024

MaxCyte to Participate in Two Upcoming Investor Conferences

GlobeNewswire October 31, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors

GlobeNewswire October 15, 2024

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 11, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

GlobeNewswire October 10, 2024

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

GlobeNewswire September 16, 2024

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

GlobeNewswire September 5, 2024

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

GlobeNewswire August 6, 2024
View More News ››

Opinion & Analysis (NDAQ:MXCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MXCT)

MaxCyte Signs Strategic Platform License with Kamau Therapeu

Breaking News: $MXCT MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies...
whytestocks - September 16, 2024

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform

Breaking News: $MXCT MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to&#xA0;Advance Next Generation Cellular...
whytestocks - July 10, 2023

MAXCYTE: A PIONEER IN THE CELL THERAPY MARKET

  $MXCT Excited to share an article about MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering-focused...
AviseAnalytics - April 17, 2023
View more Bullboard ››

Desert Gold Ventures Inc.

Desert Gold Ventures Inc.

Desert Gold Ventures Inc. is a gold exploration and development company which controls the approximately 440 square ...
View More »